Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA "Leadership Role" In Halting WHO Ephedrine Scheduling Initiative Urged

This article was originally published in The Tan Sheet

Executive Summary

FDA should take a "leadership role to assure" the World Health Organization proposal to schedule ephedrine as a controlled substance under the 1971 Convention on Psychotropic Substances "does not go forward," the D.C. firm Hyman, Phelps & McNamara asserts in Feb. 10 comments to FDA.

You may also be interested in...



Ephedrine Psychotropic Drug Classification Unwarranted - WHO Committee

Ephedrine should not be classified as a psychotropic drug by the World Health Organization, according to a report drafted by the body's 32nd Expert Committee on Drug Dependence. The report was submitted at WHO meetings in Geneva, Switzerland Sept. 12-15.

Ephedrine Psychotropic Drug Classification Unwarranted - WHO Committee

Ephedrine should not be classified as a psychotropic drug by the World Health Organization, according to a report drafted by the body's 32nd Expert Committee on Drug Dependence. The report was submitted at WHO meetings in Geneva, Switzerland Sept. 12-15.

Ephedrine Psychotropic Drug Classification Unwarranted - WHO Committee

Ephedrine should not be classified as a psychotropic drug by the World Health Organization, according to a report drafted by the body's 32nd Expert Committee on Drug Dependence. The report was submitted at WHO meetings in Geneva, Switzerland Sept. 12-15.

Topics

UsernamePublicRestriction

Register

PS089447

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel